Market Cap 80.17M
Revenue (ttm) 0.00
Net Income (ttm) -28.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 11.09
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 385,400
Avg Vol 770,466
Day's Range N/A - N/A
Shares Out 44.54M
Stochastic %K 27%
Beta -0.95
Analysts Strong Sell
Price Target $11.75

Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone l...

Industry: Biotechnology
Sector: Healthcare
Phone: 410 297 7793
Address:
115 Pullman Crossing Road, Suite 103, Grasonville, United States
mostlyzero
mostlyzero Jun. 4 at 11:06 PM
$OSTX did you forget about the DOGS?!! You can’t forget the DOGS!!
1 · Reply
Adriana88
Adriana88 Jun. 4 at 11:00 PM
$OSTX Single-asset concentration risk~
1 · Reply
mostlyzero
mostlyzero Jun. 4 at 4:12 PM
$OSTX EMA wants to wait for 3 year data end of q4. Does Craig Eagle 🦅swoop in and push AA as an “America leads the way!” Pitch to interim commish (and former WH staffer) Diamantas? Could get interesting at the early June meeting!
0 · Reply
JamesLG
JamesLG Jun. 4 at 4:03 PM
$OSTX Earnings call is on 13th August. I think the price will drop significantly due to the company bleeding money and essentially hoping for early approval. The only pathway to commercialisation without signigicant share dilution is to be granted the FDA Priority Review voucher and then sell it. Otherwise the costs associated with a Phase III trial, manufacturing scale-up and distribution will cause this price to drop like a dead pigeon.
3 · Reply
DrRivington
DrRivington Jun. 4 at 1:55 PM
$OSTX I wonder if this price consistency could mean some accumulation going on. I'm liking the lack of big price swings right now.
4 · Reply
biovaluable
biovaluable Jun. 4 at 4:22 AM
$OSTX purchase chance
2 · Reply
smallpower17
smallpower17 Jun. 4 at 2:28 AM
$OSTX https://www.moomoo.com/news/post/71008171/lake-street-maintains-os-therapies-ostxus-with-buy-rating-maintains?level=1&data_ticket=1780298487379368
0 · Reply
TeaBaggerVance
TeaBaggerVance Jun. 3 at 5:56 PM
$OSTX Made some good money trading SOAR today and I’m bringing the profits here to add to my stockpile. It’s crazy to me that we’re still allowed to buy this under $2, but I imagine that’s gonna change very, very soon. 📈📈📈
1 · Reply
Pukkaa56
Pukkaa56 Jun. 3 at 2:38 PM
$OSTX Purchased 5000
1 · Reply
Kaijieliew
Kaijieliew Jun. 3 at 2:28 PM
$OSTX added 500 shares
0 · Reply
Latest News on OSTX
OS Therapies Quarterly report: Q1 2026

May 18, 2026, 7:00 AM EDT - 17 days ago

OS Therapies Quarterly report: Q1 2026


OS Therapies Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 17 days ago

OS Therapies Earnings release: Q1 2026


OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

Apr 8, 2026, 11:38 AM EDT - 2 months ago

OS Therapies Appoints Craig Eagle, MD as Strategic Advisor


OS Therapies Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 2 months ago

OS Therapies Earnings release: Q4 2025


OS Therapies Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 2 months ago

OS Therapies Annual report: Q4 2025


OS Therapies Enters into Warrant Inducement Agreements

Jan 12, 2026, 8:01 AM EST - 5 months ago

OS Therapies Enters into Warrant Inducement Agreements


OS Therapies Provides First Half 2026 Corporate Outlook

Jan 5, 2026, 7:40 AM EST - 5 months ago

OS Therapies Provides First Half 2026 Corporate Outlook


OS Therapies Transcript: Life Sciences Virtual Investor Forum 2025

Dec 11, 2025, 10:30 AM EST - 6 months ago

OS Therapies Transcript: Life Sciences Virtual Investor Forum 2025


OS Therapies Slides: Corporate presentation

Dec 10, 2025, 7:00 AM EST - 6 months ago

OS Therapies Slides: Corporate presentation


OS Therapies Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 7 months ago

OS Therapies Earnings release: Q3 2025


OS Therapies Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 7 months ago

OS Therapies Quarterly report: Q3 2025


OS Therapies Proxy statement: Proxy Filing

Oct 17, 2025, 8:00 AM EDT - 8 months ago

OS Therapies Proxy statement: Proxy Filing


OS Therapies to Participate in Fall 2025 Conferences and Events

Oct 7, 2025, 11:50 AM EDT - 8 months ago

OS Therapies to Participate in Fall 2025 Conferences and Events


OS Therapies Terminates Equity Line of Credit

Aug 25, 2025, 9:51 PM EDT - 10 months ago

OS Therapies Terminates Equity Line of Credit


OS Therapies Proxy statement: Proxy Filing

Aug 25, 2025, 8:00 AM EDT - 10 months ago

OS Therapies Proxy statement: Proxy Filing


OS Therapies Proxy statement: Proxy Filing

Aug 25, 2025, 8:00 AM EDT - 10 months ago

OS Therapies Proxy statement: Proxy Filing


OS Therapies Quarterly report: Q2 2025

Aug 18, 2025, 6:00 PM EDT - 10 months ago

OS Therapies Quarterly report: Q2 2025


OS Therapies Earnings release: Q2 2025

Aug 18, 2025, 6:00 PM EDT - 10 months ago

OS Therapies Earnings release: Q2 2025


OS Therapies Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 10 months ago

OS Therapies Proxy statement: Proxy Filing


OS Therapies files $100M mixed securities shelf

2025-08-08T20:50:15.000Z - 10 months ago

OS Therapies files $100M mixed securities shelf


OS Therapies Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 10 months ago

OS Therapies Registration statement: Registration Filing


OS Therapies Registration statement: Registration Filing

Aug 4, 2025, 8:00 AM EDT - 10 months ago

OS Therapies Registration statement: Registration Filing


OS Therapies CEO Paul Romness sees ‘huge upside potential’

2025-07-17T19:10:39.000Z - 11 months ago

OS Therapies CEO Paul Romness sees ‘huge upside potential’


Meet OS Therapies: Fly exclusive interview with CEO Paul Romness

2025-07-17T19:10:21.000Z - 11 months ago

Meet OS Therapies: Fly exclusive interview with CEO Paul Romness


OS Therapies Registration statement: Registration Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

OS Therapies Registration statement: Registration Filing


OS Therapies reports Q1 EPS (18c), consensus (8c)

2025-05-16T10:05:35.000Z - 1 year ago

OS Therapies reports Q1 EPS (18c), consensus (8c)


OS Therapies Inc trading resumes

2025-05-07T13:15:18.000Z - 1 year ago

OS Therapies Inc trading resumes


OS Therapies Inc trading halted, news pending

2025-05-07T12:36:46.000Z - 1 year ago

OS Therapies Inc trading halted, news pending


mostlyzero
mostlyzero Jun. 4 at 11:06 PM
$OSTX did you forget about the DOGS?!! You can’t forget the DOGS!!
1 · Reply
Adriana88
Adriana88 Jun. 4 at 11:00 PM
$OSTX Single-asset concentration risk~
1 · Reply
mostlyzero
mostlyzero Jun. 4 at 4:12 PM
$OSTX EMA wants to wait for 3 year data end of q4. Does Craig Eagle 🦅swoop in and push AA as an “America leads the way!” Pitch to interim commish (and former WH staffer) Diamantas? Could get interesting at the early June meeting!
0 · Reply
JamesLG
JamesLG Jun. 4 at 4:03 PM
$OSTX Earnings call is on 13th August. I think the price will drop significantly due to the company bleeding money and essentially hoping for early approval. The only pathway to commercialisation without signigicant share dilution is to be granted the FDA Priority Review voucher and then sell it. Otherwise the costs associated with a Phase III trial, manufacturing scale-up and distribution will cause this price to drop like a dead pigeon.
3 · Reply
DrRivington
DrRivington Jun. 4 at 1:55 PM
$OSTX I wonder if this price consistency could mean some accumulation going on. I'm liking the lack of big price swings right now.
4 · Reply
biovaluable
biovaluable Jun. 4 at 4:22 AM
$OSTX purchase chance
2 · Reply
smallpower17
smallpower17 Jun. 4 at 2:28 AM
$OSTX https://www.moomoo.com/news/post/71008171/lake-street-maintains-os-therapies-ostxus-with-buy-rating-maintains?level=1&data_ticket=1780298487379368
0 · Reply
TeaBaggerVance
TeaBaggerVance Jun. 3 at 5:56 PM
$OSTX Made some good money trading SOAR today and I’m bringing the profits here to add to my stockpile. It’s crazy to me that we’re still allowed to buy this under $2, but I imagine that’s gonna change very, very soon. 📈📈📈
1 · Reply
Pukkaa56
Pukkaa56 Jun. 3 at 2:38 PM
$OSTX Purchased 5000
1 · Reply
Kaijieliew
Kaijieliew Jun. 3 at 2:28 PM
$OSTX added 500 shares
0 · Reply
BigD_Love
BigD_Love Jun. 3 at 2:03 PM
$OSTX GLTA👊🏻
2 · Reply
ZCOCSTOCK
ZCOCSTOCK Jun. 3 at 1:56 PM
$OSTX I thought $2 was the floor…hmmm
0 · Reply
3putter
3putter Jun. 3 at 1:16 PM
$OSTX for those saying that the company is going to run out of money clearly did not listen to the most recent presentation on biomarkers. The company anticipates approvals in Australia and Europe in 2026 and will actually start generating income possibly before FDA approval. The management has been very upfront when they need money and they reported feeling confident that they are good into 2027 and by that time the drug should be approved and generating significant income. This is not income dependent upon FDA approval. The income will likely come from other parts of the globe even before FDA approval.
2 · Reply
ACstranger
ACstranger Jun. 3 at 1:10 PM
$OSTX of course manipulation premarket...stealing more shares.
0 · Reply
chrisjohns
chrisjohns Jun. 3 at 12:29 PM
$OSTX Still holding the line!
0 · Reply
ACstranger
ACstranger Jun. 3 at 7:38 AM
$OSTX very always
1 · Reply
Juhanialainen
Juhanialainen Jun. 3 at 7:16 AM
$OSTX If you look at the 1M chart, those red candles are probably ATM sales. The product seems to be excellent, but the short cash runway is a bit of a burden until we get the PRV, partnership or similar uplift. Great company and great product, but we have to be realistic about the financial situation. Tax returns with some millions of dollars during the summer help a bit, but likely more dilution coming in the next 6 months. IMO that’s not a reason to sell anyway, but if the SP keeps low, that’s a great opportunity to accumulate more shares with cheap price. What often seems to be negative, is actually positive if you can be patient. Same thing was and still is with $SLS – shorts helped us long bulls to accumulate more cheap shares along the way. In the end you’ll be thankful for the bargain buys.
3 · Reply
smallpower17
smallpower17 Jun. 3 at 2:09 AM
$OSTX The 3 year survival data has been promised in "early 4Q 2026" and there will be approvals by multiple agencies immediately after that. So, at the longest, we only have 4 and a half months more to wait until we hit pay dirt.
1 · Reply
God5000
God5000 Jun. 2 at 10:11 PM
$OSTX next 1-4 weeks should be interesting, obviously survival data is significant, investors meeting going on right now for couple days, detailed data coming out by the end of the month
0 · Reply
Bunster
Bunster Jun. 2 at 9:59 PM
$OSTX what a disaster considering the data. u can spin it like all the stocktwit bulls do on a bad day or bad news. IM IN IT FOR THE LONGTERM 50 DOLLARS IN THREE YEARS NONSENSE. At least folks are smart enough to talk about offerings and if we get the voucher not when we get it. No question bad luck and timing on our release for the bios to get destroyed..i could not sell all my shares so i be still here
3 · Reply
BostonDave
BostonDave Jun. 2 at 8:05 PM
$OSTX The whole sector was crushed today. OSTX will be fine. They won't need to raise money if they get the PRV.
2 · Reply
ACstranger
ACstranger Jun. 2 at 8:00 PM
$OSTX os of 75% after 2,5 years is very good. If trent continues than os after 3 years will also be at 75%.
0 · Reply